MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$102.46 |
52 Week High | US$148.18 |
52 Week Low | US$64.46 |
Beta | 1.6 |
1 Month Change | 19.71% |
3 Month Change | 13.05% |
1 Year Change | -25.06% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -47.76% |
Recent News & Updates
Recent updates
Shareholder Returns
MRNA | AT Biotechs | AT Market | |
---|---|---|---|
7D | 9.1% | 4.3% | 1.5% |
1Y | -25.1% | -2.7% | 6.5% |
Return vs Industry: MRNA underperformed the Austrian Biotechs industry which returned -1.1% over the past year.
Return vs Market: MRNA underperformed the Austrian Market which returned 6.9% over the past year.
Price Volatility
MRNA volatility | |
---|---|
MRNA Average Weekly Movement | 8.3% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.3% |
10% most volatile stocks in AT Market | 4.8% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: MRNA has not had significant price volatility in the past 3 months.
Volatility Over Time: MRNA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | https://www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
MRNA fundamental statistics | |
---|---|
Market cap | €37.99b |
Earnings (TTM) | -€4.35b |
Revenue (TTM) | €6.33b |
6.2x
P/S Ratio-9.0x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRNA income statement (TTM) | |
---|---|
Revenue | US$6.85b |
Cost of Revenue | US$9.54b |
Gross Profit | -US$2.69b |
Other Expenses | US$2.02b |
Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -12.31 |
Gross Margin | -39.28% |
Net Profit Margin | -68.84% |
Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison